Unraveling the therapeutic benefit of sequenced chemo-immunotherapy.
Unraveling the therapeutic benefit of sequenced chemo-immunotherapy.
复制标题
揭示序贯化学免疫疗法的治疗益处。
DOI：
10.1158/1078-0432.ccr-23-3736
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Luke,JasonJ
中科院分区：
文献类型：
--
作者：
Vignali,PaoloDA;Luke,JasonJ
联合免疫检查点抑制与化疗是一种临床标准，但同时给药可能会通过钝化CD8 T细胞的增殖和分化来限制免疫治疗的全部益处。确定序贯化学免疫治疗或单独免疫治疗可行的患者应该是优化长期结果的优先事项。第1833页
Combination immune-checkpoint inhibition with chemotherapy is a clinical standard, yet concurrent administration may limit the full benefit of immunotherapy by blunting the proliferation and differentiation of CD8 T cells. Identifying patients in whom sequential chemo-immunotherapy or immunotherapy alone is feasible should be a priority to optimize long-term outcomes.See related article by Mariniello et al., p. 1833